Cannabis Use Disorder Treatment and Reimbursement

  • Andrew M. Kiselica
  • Amy DuhigEmail author


Cannabis use disorders (CUD) are associated with medical and psychosocial complications. Some psychosocial interventions have shown modest efficacy to treat this disorder. They include cognitive-behavioral, motivational interviewing, contingency management, and relapse prevention approaches. A meta-analysis of randomized controlled trials demonstrated a moderate overall effect size for these treatments—patients receiving an evidence-based psychotherapy fared better than 66% of individuals in the control conditions. There are no medications approved by the Food and Drug Administration (FDA) for the treatment of CUD. There is a dearth of evidence on the type of treatments offered/available to treatment-seeking individuals with CUD. Consequently, it remains unclear whether these evidence-based therapies are being accessed by patients. It has been reported that most patients with CUD do not participate in any treatment, let alone an evidence-based one. The purpose of the current chapter is to review available literature on access to and reimbursement of treatments for CUDs. The chapter includes the opinion of treatment payers about treatments for CUD and insights for researchers and medication development sponsors.


Treatment Reimbursement Payers Sponsors 


  1. 1.
    Chabrol H, Chauchard E, Mabila JD, Mantoulan R, Adèle A, Rousseau A. Contributions of social influences and expectations of use to cannabis use in high-school students. Addict Behav. 2006;31(11):2116–9. Scholar
  2. 2.
    O’Callaghan FV, Joyce J. Cannabis: what makes university students more or less likely to use it? J Appl Biobehav Res. 2006;11(2):105–13. Scholar
  3. 3.
    Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. Drug Alcohol Depend. 2014;140:145–55. Scholar
  4. 4.
    Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29. Scholar
  5. 5.
    Madras BK. Cannabis and medicinal properties. In:Addressing the challenges of prescribing controlled drugs; 2016. p. 34.Google Scholar
  6. 6.
    Noel C. Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders. Ment Health Clin. 2017;7(1):29–38.CrossRefGoogle Scholar
  7. 7.
    Agrawal A, Pergadia ML, Lynskey MT. Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict. 2008;17(3):199–208. Scholar
  8. 8.
    Budney AJ. Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction. 2006;101:125–33. Scholar
  9. 9.
    Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatr. 2004;161(11):1967–77.CrossRefGoogle Scholar
  10. 10.
    Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction. 2008;103(5):787–99. Scholar
  11. 11.
    Davis JP, Smith DC, Morphew JW, Lei XR, Zhang SJ. Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: a prospective study. J Drug Issues. 2016;46(1):64–83. Scholar
  12. 12.
    Greene MC, Kelly JF. The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: a 12-month prospective investigation. J Addict Med. 2014;8(5):359–67. Scholar
  13. 13.
    Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BE. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry. 2008;69(9):1354–63.CrossRefGoogle Scholar
  14. 14.
    APA. Diagnostic and statistical manual of mental disorders. Washington, DC: Author; 2013.Google Scholar
  15. 15.
    Hasin DS, Kerridge BT, Saha TD, Huang BJ, Pickering R, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016;173(6):588–99. Scholar
  16. 16.
    Green KM, Musci RJ, Johnson RM, Matson PA, Reboussin BA, Ialongo NS. Outcomes associated with adolescent marijuana and alcohol use among urban young adults: a prospective study. Addict Behav. 2016;53:155–60. Scholar
  17. 17.
    Griffith-Lendering MFH, Huijbregts SCJ, Mooijaart A, Vollebergh WAM, Swaab H. Cannabis use and development of externalizing and internalizing behaviour problems in early adolescence: a TRAILS study. Drug Alcohol Depend. 2011;116(1–3):11–7. Scholar
  18. 18.
    Griffith-Lendering MFH, Wigman JTW, van Leeuwen AP, Huijbregts SCJ, Huizink AC, Ormel J, et al. Cannabis use and vulnerability for psychosis in early adolescence-a TRAILS study. Addiction. 2013;108(4):733–40. Scholar
  19. 19.
    Ganzer F, Bröning S, Kraft S, Sack P-M, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26(2):186–222. Scholar
  20. 20.
    Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679–89. Scholar
  21. 21.
    Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015;112:271–8.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Brook JS, Stimmel MA, Zhang CS, Brook DW. The association between earlier marijuana use and subsequent academic achievement and health problems: a longitudinal study. Am J Addict. 2008;17(2):155–60. Scholar
  23. 23.
    Danielsson AK, Agardh E, Hemmingsson T, Allebeck P, Falkstedt D. Cannabis use in adolescence and risk of future disability pension: a 39-year longitudinal cohort study. Drug Alcohol Depend. 2014;143:239–43. Scholar
  24. 24.
    Hara M, Huang DYC, Weiss RE, Hser YI. Concurrent life-course trajectories of employment and marijuana-use: exploring interdependence of longitudinal outcomes. J Subst Abuse Treat. 2013;45(5):426–32. Scholar
  25. 25.
    Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. Pharmacotherapy. 2016;36(5):511–35. Scholar
  26. 26.
    Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JAJ. Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof. 2015;38(1):94–114. Scholar
  27. 27.
    Budney AJ, Roffman R, Stephens R, Walker D. Marijuana dependence and its treatment. Alcohol. 2007;50:60.Google Scholar
  28. 28.
    Kazdin AE. Behavior modification in applied settings. Waveland Press; 2012.Google Scholar
  29. 29.
    Gates P, Copeland J, Swift W, Martin G. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev. 2012;31(3):311–9. Scholar
  30. 30.
    Luoma JB, Kulesza M, Hayes SC, Kohlenberg B, Larimer M. Stigma predicts residential treatment length for substance use disorder. Am J Drug Alcohol Abuse. 2014;40(3):206–12. Scholar
  31. 31.
    Alexandre PK, Beulaygue IC, French MT, McCollister KE, Popovici I, Sayed BA. The economic cost of substance abuse treatment in the state of Florida. Eval Rev. 2012;36(3):167–85. Scholar
  32. 32.
    Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64(9):863–70. Scholar
  33. 33.
    Goodwin LR, Sias SM. Severe substance use disorder viewed as a chronic condition and disability. J Rehabil. 2014;80(4):42–9.Google Scholar
  34. 34.
    Murphy SM, Campbell ANC, Ghitza UE, Kyle TL, Bailey GL, Nunes EV, Polsky D. Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial. Drug Alcohol Depend. 2016;161:119–26. Scholar
  35. 35.
    Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost-effectiveness of four treatments for marijuana dependence. Addiction. 2007;102(9):1443–53. Scholar
  36. 36.
    Wickizer TM, Mancuso D, Huber A. Evaluation of an innovative medicaid health policy initiative to expand substance abuse treatment in Washington State. Med Care Res Rev. 2012;69(5):540–59. Scholar
  37. 37.
    Humphreys K, Wagner TH, Gage M. If substance use disorder treatment more than offsets its costs, why don’t more medical centers want to provide it? A budget impact analysis in the Veterans Health Administration. J Subst Abuse Treat. 2011;41(3):243–51. Scholar
  38. 38.
    George Washington University Medical Center. In: G. W. U. M. Center, editor. Detailed information about coding for SBI reimbursement. Washington, DC: George Washington University Medical Center.Google Scholar
  39. 39.
    Sterling S, Weisner C, Hinman A, Parthasarathy S. Access to treatment for adolescents with substance use and co-occurring disorders: challenges and opportunities. J Am Acad Child Adolesc Psychiatry. 2010;49(7):637–46.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Committee on Substance Abuse. Substance use screening, brief intervention, and referral to treatment for pediatricians. Am Acad Pediatrics. 2011.Google Scholar
  41. 41.
    Bouchery EE, Harwood HJ, Dilonardo J, Vandivort-Warren R. Type of health insurance and the substance abuse treatment gap. J Subst Abus Treat. 2012;42(3):289–300. Scholar
  42. 42.
    Clark DB, Moss HB. Providing alcohol-related screening and brief interventions to adolescents through health care systems: obstacles and solutions. PLoS Med. 2010;7(3):e1000214.CrossRefGoogle Scholar
  43. 43.
    Mark TL, Hodgkin D, Levit KR, Thomas CP. Growth in spending on and use of services for mental and substance use disorders after the great recession among individuals with private insurance. Psychiatr Serv. 2016;67(5):504–9. Scholar
  44. 44.
    Mark TL, Levit KR, Yee T, Chow CM. Spending on mental and substance use disorders projected to grow more slowly than all health spending through 2020. Health Aff. 2014;33(8):1407–15. Scholar
  45. 45.
    Humphreys K, Frank RG. The Affordable Care Act will revolutionize care for substance use disorders in the United States. Addiction. 2014;109(12):1957–8. Scholar
  46. 46.
    Humphreys K, McLellan AT. Brief intervention, treatment, and recovery support services for Americans who have substance use disorders: an overview of policy in the Obama administration. Psychol Serv. 2010;7(4):275–84. Scholar
  47. 47.
    Levit KR, Stranges E, Coffey RM, Kassed C, Mark TL, Buck JA, Vandivort-Warren R. Current and future funding sources for specialty mental health and substance abuse treatment providers. Psychiatr Serv. 2013;64(6):512–9. Scholar
  48. 48.
    Kaplan T, Pear R. House passes measure to repeal and replace the Affordable Care Act. New York Times. 2017, May 4. Retrieved from
  49. 49.
    Wen HF, Cummings JR, Hockenberry JM, Gaydos LM, Druss BG. State parity laws and access to treatment for substance use disorder in the United States implications for federal parity legislation. Jama Psychiatry. 2013;70(12):1355–62. Scholar
  50. 50.
    Saloner B, Bandara SN, McGinty EE, Barry CL. Justice-involved adults with substance use disorders: coverage increased but rates of treatment did not in 2014. Health Aff. 2016;35(6):1058–66. Scholar
  51. 51.
    Barry CL, Chien AT, Normand SLT, Busch AB, Azzone V, Goldman HH, Huskamp HA. Parity and out-of-pocket spending for children with high mental health or substance abuse expenditures. Pediatrics. 2013;131(3):E903–11. Scholar
  52. 52.
    Busch SH, Epstein AJ, Harhay MO, Fiellin DA, Un H, Leader D, Barry CL. The effects of Federal Parity on substance use disorder treatment. Am J Manag Care. 2014;20(1):76–82.PubMedPubMedCentralGoogle Scholar
  53. 53.
    McConnell KJ, Ridgely MS, McCarty D. What Oregon’s parity law can tell us about the federal Mental Health Parity and Addiction Equity Act and spending on substance abuse treatment services. Drug Alcohol Depend. 2012;124(3):340–6. Scholar
  54. 54.
    Acri J, Skolnick P. Pharmacotherapy of substance use disorders. In:Neurobiology of mental illness. London: Oxford University Press; 2013. p. 235–45.Google Scholar
  55. 55.
    Kiselica AM, Duhig A, Montoya I, Floyd J, Byars C. A survey of payer perspectives on cannabis use disorder. under review.Google Scholar
  56. 56.
    Strain EC. Incorporating alcohol pharmacotherapies into medical practice: a treatment improvement protocol. DIANE Publishing; 2010.Google Scholar
  57. 57.
    Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147–56. Scholar
  58. 58.
    Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to addiction pharmacotherapy in private health plans. J Subst Abuse Treat. 2016;66:23–9. Scholar
  59. 59.
    Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114(2–3):201–6. Scholar
  60. 60.
    Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J. Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat. 2015;55:1–5. Scholar
  61. 61.
    Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2007;86(2–3):214–21. Scholar
  62. 62.
    Harris KM, DeVries A, Dimidjian K. Datapoints: trends in naltrexone use among members of a large private health plan. Psychiatr Serv. 2004;55(3):221–221.CrossRefGoogle Scholar
  63. 63.
    Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–93.CrossRefGoogle Scholar
  64. 64.
    Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol. 2006;26:S13–9. Scholar
  65. 65.
    Abraham AJ, Knudsen HK, Roman PM. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation. J Stud Alcohol Drugs. 2011;72(4):669–77.CrossRefGoogle Scholar
  66. 66.
    Oser CB, Roman PM. Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. J Stud Alcohol Drugs. 2007;68(6):852–61.CrossRefGoogle Scholar
  67. 67.
    Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43(3):951–70. Scholar
  68. 68.
    Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–9. Scholar
  69. 69.
    Gastfriend DR. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. In: Uhl GR, editor. Addiction reviews, vol. 1327; 2014. p. 112–30.Google Scholar
  70. 70.
    Kranzler HR, Montejano LB, Stephenson JJ, Wang SH, Gastfriend DR. Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population. Alcohol Clin Exp Res. 2010;34(6):1090–7. Scholar
  71. 71.
    Harris AHS, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679–85. Scholar
  72. 72.
    Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor R, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171.CrossRefGoogle Scholar
  73. 73.
    Jarosz J, Miernik K, Wachal M, Walczak J, Krumpl G. Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2013;39(3):144–60. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Miami VA Healthcare SystemMiamiUSA
  2. 2.University of South FloridaTampaUSA
  3. 3.HEOR/Global Value Strategy, Xcenda LLCFort MillUSA
  4. 4.Consulting Services. Xcenda LLCPalm HarborUSA

Personalised recommendations